Sirio Pharma, a nutraceutical contract development and manufacturing organization (CDMO), will launch GummiBiotics supplements at CPHI Milan. The gummies each contain pro- and postbiotics for immune support, digestive support, and weight management/loss.
 
GummiBiotics Defense contains 500 mg of EpiCor postbiotic per serving, with added zinc, to support normal function of the immune system. It is the first gummy to feature EpiCor, a postbiotic clinically evidenced to support immune function and gut health.
 
Sirio has also launched GummiBiotics IBS Ease, featuring ADM’s ES1 postbiotic which, in clinical studies, was evidenced to moderate some symptoms of IBS-D.  The gummy is further enhanced with xylo-oligosaccharides, which are evidenced to improve symptoms of IBS-D, as well as calcium, which contributes to the normal functioning of digestive enzymes.
 
GummiBiotics Lean features a formulation of apple cider vinegar, vitamin B6, and DE111 probiotic, a strain of Bacillus subtilis which is evidenced to support weight management/weight loss. The gummy also contains Sirio’s own Apple Cider Vinegar Natuful Postbiotic.
 
“At SIRIO we are very proud of our R&D capabilities, where we continue to invest a significant portion of our earnings: our technical and formulation teams account for 13% of our total employee base, something unique for a CDMO,” said Sara Lesina, general manager of Sirio Europe and Americas. “We are constantly working with our customers and our experts to not just follow the trends but make first-in-class new products that will drive sales in new areas – and each one of these concepts is a true first for nutraceutical brands. So we are incredibly excited to launch the new GummiBiotics range as it continues building on our partnerships with some of the best ingredient suppliers and it combines the benefits of science-backed biotics with gummies that are truly delicious: this range will completely change the experience for consumers.”